{"id":1036346,"date":"2012-05-30T04:24:15","date_gmt":"2012-05-30T04:24:15","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/beike-earns-aabb-accreditation-for-cord-blood-and-cord-tissue-banking.php"},"modified":"2024-08-17T15:55:42","modified_gmt":"2024-08-17T19:55:42","slug":"beike-earns-aabb-accreditation-for-cord-blood-and-cord-tissue-banking","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/beike-earns-aabb-accreditation-for-cord-blood-and-cord-tissue-banking.php","title":{"rendered":"Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking"},"content":{"rendered":"<p><p>    SHENZHEN, China, May 29, 2012 \/PRNewswire-Asia\/    --Beike Biotechnology Co., Ltd    (\"Beike\") announced that it has been awarded AABB accreditation    for cord blood and cord tissue banking. This accreditation has    been granted following an intensive on-site assessment by AABB    assessors and establishes that the level of medical, technical    and administrative performance within the facility is in    accordance with the AABB standards or exceeds those set by    AABB. With this achievement, Beike becomes China's first and    only AABB-accredited stem cell bank for both cord blood and    cord tissue banking.  <\/p>\n<p>    Ying Song, MD, PhD, Medical Director of Beike, stated, \"It is a    proud moment for us that Beike is the first and the only stem    cell bank in China to possess AABB accreditation for both cord    blood and cord tissue and this reflects our commitment to    quality. It is also noteworthy to mention that Beike is among    the first stem cell banks in the world to receive AABB    accreditation for cord tissue banking which positions Beike as    a leader in stem cell preservation.\"  <\/p>\n<p>    Beike began the comprehensive AABB accreditation process in    March 2010 and completed the on-site assessment in September    2011. The accreditation assessment included stem cell    processing, records, document control, inspection and testing,    technician training, sample identification, traceability and    validations. During this audit, it was determined that Beike's    medical, technical and administrative performance met the    standards set by the AABB. Beike was issued its AABB    certificate in January 2012.  <\/p>\n<p>    Dr. Shengqin Ye, President of Beike, commented, \"We are    extremely pleased to have been granted this accreditation. With    this, Beike has once again demonstrated a commitment to    advanced learning, continuous improvement and innovation to    sustain the highest possible level of quality and safety.\"  <\/p>\n<p>    To meet AABB standards, Beike adopted new technology for stem    cell processing (AXP AutoXpress system), storage (BioArchive    Systems), and testing (Beckman hematology analyzer LH750 and    Tecan Freedom EVOlyzer). Additionally, the company optimized    its information technology platform and software systems,    adding an advanced bar code management system, real-time    monitoring capabilities, and an advanced enterprise resource    planning (ERP) system to its call center.  <\/p>\n<p>    About Beike Biotechnology Company:  <\/p>\n<p>    Shenzhen Beike Biotechnology Co., Ltd. is    China's leading biotechnology company focusing on    banking adult stem cells and developing    new cell based medicinal products. Headquartered    in Shenzhen (near Hong Kong) with a flagship regenerative    medicine facility at the China Medical City in Jiangsu    province, Beike produces a full line of stem cell products    derived from umbilical cord, cord blood and autologous bone    marrow.  <\/p>\n<p>    About AABB:  <\/p>\n<p>    AABB (formerly the American Association of    Blood Banks) is an international non-profit body dedicated to    developing the highest standards in blood and cord blood    banking, transfusion medicine and cellular therapy. The    association is committed to improving health by developing and    delivering standards, accreditation and educational programs    that focus on optimizing patient and donor care and safety.  <\/p>\n<p>    Based in the United States, AABB represents more than 2,000    institutions and 8,000 individuals in 80 countries, involved in    collecting, processing, testing, distributing, or transfusing    blood, blood components, or cellular therapy products.  <\/p>\n<\/p>\n<p>Read more here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/beike-earns-aabb-accreditation-cord-140000955.html;_ylt=A2KJjb3YoMVP5nIASgX_wgt.\" title=\"Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking\" rel=\"noopener\">Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SHENZHEN, China, May 29, 2012 \/PRNewswire-Asia\/ --Beike Biotechnology Co., Ltd (\"Beike\") announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB. With this achievement, Beike becomes China's first and only AABB-accredited stem cell bank for both cord blood and cord tissue banking <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/beike-earns-aabb-accreditation-for-cord-blood-and-cord-tissue-banking.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-1036346","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036346"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1036346"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1036346\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1036346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1036346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1036346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}